| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01542242 Details | 2015-12-09 Interventional | 4 | 1 | Liraglutide Diabetes Mellit… Diabetes Mellit… Prader-Willi Sy… Syndrome Diabetes Mellit… Prader Willi Sy… | Subject withdrew - | |||
| NCT00076206 Details | 2015-12-09 Interventional | 2 | - | Temsirolimus Arthritis Arthritis, Rheu… Rheumatoid Arth… | - - | |||
| NCT00864513 Details | 2015-12-08 Interventional | 2 | 17 | Pemetrexed Pancreatic Neop… Pancreas Cancer | At interim analysis the study did not meet the response criteria to continue study was closed at interim analysis so only 12 subjects were evaluable for response, 15 subjects received treatment and were evaluable for adverse events | |||
| NCT02054936 Details | 2015-12-07 Interventional | 4 | 0 | Rivaroxaban Warfarin Complications; … | Change in standard of care, no possibility of recruitment - | |||
| NCT00754884 Details | 2015-12-04 Interventional | 4 | 0 | Calcitonin Calcitonin Gene… Glycerol Katacalcin Salmon calciton… Fibromyalgia Myofascial Pain… | Study drug was not longer available in our country. - | |||
| NCT00538187 Details | 2015-12-04 Interventional | 1 | 18 | Bortezomib Obatoclax Leukemia, Lymph… Lymphoma Lymphoma, Folli… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Recurrence Adult Non-Hodgk… Recurrent Adult… Recurrent Grade… Recurrent Grade… Recurrent Grade… Recurrent Mantl… Recurrent Margi… Recurrent Small… | - - | |||
| NCT00381836 2005-005658-37 Details | 2015-12-04 Interventional | 2/3 | - | Darbepoetin alf… Anemia Prostatic Neopl… | Terminated by sponsor due to general risk that aranesp caused tumor progression - | |||
| NCT02177760 Details | 2015-12-03 Interventional | 2 | 0 | Sirolimus Immunologic Def… Severe Combined… Stem Cell Trans… Transplacental … | Preliminary data suggested a better approach available - | |||
| NCT00970086 Details | 2015-12-03 Interventional | 4 | 22 | Bupivacaine Levobupivacaine Pain, Postopera… Postoperative P… Reaction; Anest… | Groin surgery was changed to a laparoscopic technique; recruitable patients ceased. - | |||
| NCT00599131 Details | 2015-12-03 Interventional | 2 | 4 | Cetuximab Docetaxel Fluorouracil Laryngeal Neopl… Cancer of Laryn… | The study was discontinued prematurely due to early stopping rules. The study was discontinued prematurely due to an early stopping rule. | |||
| NCT01953744 Details | 2015-12-02 Interventional | 3 | 53 | Fluconazole Meglumine Antim… Leishmaniasis Leishmaniasis, … Cutaneous Leish… | Low cure rate in the study (fluconazole) group - | |||
| NCT01730495 2011-006069-16 Details | 2015-12-02 Interventional | 2 | 4 | Etanercept Encephalomyelit… Fatigue Fatigue Syndrom… Myalgia Necrosis Syndrome Chronic Fatigue… Myalgic Encepha… | After inclusion of four patients, two experienced moderate worsening of symptoms - | |||
| NCT01600963 2011-000653-23 Details | 2015-12-02 Interventional | 3 | 0 | Bedaquiline Diarylquinoline… Tuberculosis Tuberculosis, M… Multi-drug Resi… | PhIII program revised; TMC207-C210 cancelled - | |||
| NCT00313612 Details | 2015-11-27 Interventional | 2 | [1 Refs] | 39 | Oxaliplatin Topotecan Carcinoma, Ovar… Recurrent Ovari… | - - | ||
| NCT02336308 Details | 2015-11-26 Interventional | 4 | 0 | Ketamine Hyperalgesia Anxiety Pain Thermal Hyperal… | Standard of care for dressing changes at the institution now includes treatment intervention - | |||
| NCT01381731 Details | 2015-11-25 Interventional | 2 | 14 | Ophthalmic Solu… Photorefractive… | - - | |||
| NCT02106520 Details | 2015-11-20 Interventional | 2/3 | 80 | Bevacizumab Epistaxis Telangiectasia,… Telangiectasis Hereditary Hemo… | DSMB's decision following the first step analysis - | |||
| NCT00988169 Details | 2015-11-20 Interventional | 2 | 6 | Erlotinib Hydro… Lung Neoplasms Lung Cancer | - - | |||
| NCT00982657 2010-022657-42 Details | 2015-11-20 Interventional | 2 | 34 | Sunitinib Carcinoma, Rena… Solid Tumor | Refer to statement in Summary Section/Detailed Description On 25 Oct 2012, due to data safety signals in separate clinical trial with CVX-060, all CVX-060 studies were discontinued. Ongoing participants in B1131001 were permitted to remain on study at a reduced dose if determined to derive clinical benefit. | |||
| NCT00975416 Details | 2015-11-20 Interventional | 4 | 63 | Oxytocin Substance-Relat… Drug Dependence | - 1 participant committed suicide outside of that occurred outside of adverse event time frame. There were 12 occurrences of computer malfunction during the study. This did not effect data collection for primary outcome measures. |